• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Use of phytic acid or its salts alone or in combination with vitamins b6 for the prevention of the formation of advanced glycation products. The present invention relates to the use of phytate or any of its salts to prevent the formation of advanced glycation end products (age), toxic products that are produced in pathologies such as diabetes, either alone or in combination with b6 vitamers such as pyridoxamine and forming part of a medicament or a pharmaceutical composition prepared to be administered orally, rectally, subcutaneously, intraarterially, intramuscularly, intraspinally, intracranially, intravenously or inhaled. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2596752A1
    申请号:ES201531010
    申请日:2015-07-10
    公开日:2017-01-11
    发明作者:Félix Grases Freixedas；Antonia Costa Bauza；Miquel ADROVER ESTELRICH；Francisco BERGA MONTANER；Pilar SANCHÍS CORTÉS；Luis MASMIQUEL COMAS；Rosmeri RIVERA IROGOIN；Regina FORTUNY MARQUÉS
    申请人:Universitat de les Illes Balears；Servei de Salut de Les Illes Balears IBSalut；
    IPC主号:
    专利说明:

    The present invention relates to the use of phytate or any of its salts to prevent the formation of advanced glycation end products (AGE) that occur in pathologies such as diabetes, either alone or in combination with B6 vitamins such as pyridoxamine and forming part of a drug or pharmaceutical composition prepared to be administered orally, rectally, subcutaneously, intraarterially, intramuscularly, intraspinally, intracranially, intravenously or inhalatively. Both phytate and Vitamin B6 have a capacity to inhibit the formation of AGEs, so they can be used for therapeutic purposes in the treatment or prevention of diseases that appear as a result of the formation of AGEs, such as neuropathy, nephropathy, atherosclerosis , vascular calcification and neurodegenerative diseases (Alzheimer's and Parkinson's). STATE OF THE TECHNIQUE
    Diabetes mellitus (DM) is a chronic pathology that involves the development of various metabolic disorders due to an increase in the concentration of blood glucose. The increase in glycemic levels in diabetic patients can lead to the development of a wide range of metabolic disorders, the concrete importance of which will depend on the particular pathophysiology of each diabetic. Among them, nephropathy or diabetic heart disease, as well as the high predisposition of diabetics to develop various neurodegenerative events. These pathologies are directly induced by hyperglycemia through the nonspecific chemical interaction between reducing sugars (essentially glucose) and different biological macromolecules. This process, known as non-enzymatic glycation, leads to structural and functional deterioration of the molecules on which it occurs, consequently inducing pathological development.
    Although glycation can occur on most biomolecules, such as lipid bilayers or on DNA, the majority of pathologies associated with DM


    they appear due to the non-enzymatic glycation of proteins (GP) that have a low turnover rate. Thus, the GP begins with the condensation between the protein amino groups (present in the side chains of arginines and lysines) with glucose or other reducing carbohydrates. As a result of said condensation, a glucid Schiff base is formed, which reorders irreversibly to give an Amadori compound. Subsequently, this compound evolves through different mechanisms towards the formation of the final products of glycation, commonly known as AGEs ("advanced gycation end-products"). In parallel, both glucose, Schiff's base and Amadori compound can undergo auto-oxidation reactions, which produce free radicals and small highly reactive carbonyl compounds, which can react again with other amino acids, inducing the formation of new AGEs, and increasing the protein damage initiated in the first instance by glucose.
    Thus, AGEs constitute a heterogeneous family of compounds whose chemical nature depends on the type of protein residue that reacts, on their environment and on the type of glycating agent. Although its pathological action focuses on the structural and functional modification that its formation entails (eg HbA1c glycated hemoglobin has a lower affinity towards oxygen than the native one), its interaction with its specific receptors (known as RAGEs) not only induces a pro-inflammatory process, but also increases oxidative stress which essentially affects the vascular system. Additionally, it has also been observed that AGEs induce cell apoptosis.
    As a whole, the levels of circulating AGEs in blood of patients with DM are generally much higher than those of healthy people. Although, these levels are the result of a delicate balance between their endogenous production, exogenous intake, their endogenous degradation (by specific enzymes such as glioxalases I, II and carbonylreductase) and their renal excretion. Thus, the alteration of said balance by any pathophysiological factor (such as hyperglycemia) can lead to pathological development.
    A large part of the therapeutic strategy aimed at reducing the predisposition of diabetics to suffer pathologies induced by an increase in circulating AGEs.


    He has focused on the search for small compounds that inhibit their formation. One of the most commonly used clinically today is metformin, which decreases hepatic glucose production and increases muscle absorption. In turn, it has also been seen that it is able to significantly reduce the formation of AGEs both in vitro and in vivo, by sequestering carbonyl compounds with high glycant capacity formed during glucose oxidations, Schiff base and Amadori compound (eg glyoxal or methylglyoxal). However, this is the only mechanism of action by which metformin can inhibit glycation, since it is not able to sequester the free radicals formed during the GP, nor chelate the Cu2 + or Fe3 + ions that catalyze the different stages of the GP . This implies that it can only act effectively at high doses (doses of 500-800 mg every 8-12 hours), which can cause side effects in the medium and long term in one in ten patients treated as nausea, vomiting, diarrhea or loss of appetite. Therefore, much of the current research in the field of DM focuses on the search for natural molecules that can inhibit the formation of AGEs through different complementary mechanisms of action. This would allow the administration of lower doses minimizing adverse effects.
    Phytate is a naturally occurring phosphorus compound that has been administered to diabetic patients in order to control blood sugar levels (EP0342955) or reduce symptoms associated with diabetes such as circulatory problems, paraesthesia or pain (Sánchez López E. Rev Clin. Esp. 15 Nov 1969, vol. 115, nº 3, p. 219-226).
    Another natural compound of interest is pyridoxamine (PM), a vitamin of vitamin B6 that is abundantly found in the liver. Its administration considerably reduces AGEs formation in both animal models and diabetic individuals (application WO2004112788) through different mechanisms that act in a complementary way: a) sequestration of carbonyl compounds with high glycan capacity; b) formation of weak metal complexes with the Cu2 + and Fe3 + ions, which catalyze the GP; c) neutralization of free radicals formed during the GP; and d) reduction of cell apoptosis. The discovery of these characteristics of high pharmacological potential has led to their protection as a treatment to combat diabetic retinopathy (WO2004112788), as part


    of a topical composition to reduce the formation of AGEs on the skin (US 7,666,442 B2) or as an inhibitor of diabetes complications (US 2005/0014799 A1). In turn, its beneficial effect in the treatment of diabetic retinopathy has been found (Stitt A, et al., Diabetes, 2002, 51, 2826-2832). DESCRIPTION OF THE INVENTION
    The present invention aims at the use of phytate or any of its salts, only
    or in combination with Vitamin B6 to prevent the formation of AGEs and the development of pathologies associated with diabetes in patients suffering from such disorder, where phytate alone or in combination with Vitamin B6 can be part of a drug or pharmaceutical composition prepared for be administered orally, rectally, subcutaneously, intraarterially, intramuscularly, intraspinally, intracranially, intravenously or inhalationally. These inhibitors of the formation of AGEs, related to the aspects described in the state of the art section and in the recent discoveries of the applicants on the combination of phytic acid and / or its pharmaceutically acceptable phytates with B6 vitamins such as pyridoxamine, can be used for therapeutic purposes in the treatment of diseases that appear as a result of the formation of AGEs, as many of the pathologies associated with diabetes would be. The use of phytic acid and / or its phytates with Vitamin B6 and / or analogous molecules, in isolation or in combination, has not been described above and can be very beneficial for the treatment of diabetic patients, since it can significantly decrease the formation from AGEs.
    Therefore, in a first aspect the present invention relates to the use of a composition comprising phytate or any of its salts for the manufacture of a medicament for the prevention of the formation of glycation end products or AGEs in diabetic patients, wherein said The drug is prepared for oral, rectal, subcutaneous, intraarterial, intramuscular, intraspinal, intracranial, intravenous or inhalation administration.
    In a preferred embodiment, the composition further comprises a vitreous B6 or any of its salts. In a more preferred embodiment the vitreous B6 is selected from pyridoxine, pyridoxal or pyridoxamine and more preferably, pyridoxamine.


    In another preferred embodiment, the phytic acid salts are selected from sodium phytate, potassium phytate, calcium phytate, magnesium phytate, zinc phytate, calcicomagnesic phytate or combinations thereof. In a more preferred embodiment, the salt of phytic acid is calcium-magnesium phytate.
    In another preferred embodiment, the phytic acid or its salts come from a part of a plant species rich in phytic acid or its salts, or from a plant extract of said species.
    Another aspect of the invention relates to the use of a composition comprising phytic acid or any of its pharmaceutically acceptable salts combined sequentially, simultaneously or separately with a B6 vitramer, for the manufacture of a medicament for the prevention of the formation of AGEs. in diabetic patients.
    Another aspect of the invention relates to a composition comprising phytic acid
    or any of its salts and at least one derivative of vitamin B6 or any of its salts.
    In a preferred embodiment, this composition further comprises a vitreous B6 or any of its salts. In a preferred embodiment, vitreous B6 is selected from pyridoxine, pyridoxal or pyridoxamine and more preferably, pyridoxamine.
    In another preferred embodiment, the phytic acid salt included in this composition is selected from sodium phytate, potassium phytate, calcium phytate, magnesium phytate, zinc phytate, calcium-magnesium phytate or combinations thereof. More preferably, the salt of phytic acid is calcium-magnesium phytate.
    In another preferred embodiment, the phytic acid or its salts come from a part of a plant species rich in phytic acid or its salts, or from a plant extract of said species.
    In the present invention, "phytate" or "myo-inositol-hexaphosphate" means the molecule of formula:


    and its pharmaceutically acceptable salts, which include but are not limited to sodium, potassium, calcium, magnesium, zinc and calcium-magnesium salts. For the purpose of the
    In the present invention, phytic acid and / or its pharmaceutically acceptable salts can be used freely as pure substances, extracts of plant species that contain them, such as, for example, brown rice extracts, or transported in plant species that contain them, such as they can be the germs or external parts of the grains or fruits of wheat, oats, soy, almond, garrofín, etc.
    In the present invention, "Vitamin B6" or "Vitamin B6" means all those compounds represented in the following molecule, as well as their pharmaceutically acceptable ionic forms.
    R4
    R5 R3
    R6NR2
    R2, R6 = H, CH3, (CH2) nCH3, OH, (CH2) nOH, NH2, (CH2) nNH2, N (CH3) n, (CH2) nN (CH3) n '
    R3, R5 = H, NH2, SH2, OH, (CH2) nNH2, (CH2) nSH2, (CH2) nCOH R4 = NH2, (CH2) NH2, SH2, (CH2) nSH2, COH, OH, (CH2) OH , (CH2) nCOH, COOH, (CH2) nCOOH
    n n
    In another preferred embodiment, the medicament is in a form suitable for administration orally, parenterally, intravenously or enterally.
    In another preferred embodiment, the composition of the invention comprises between 20-50%
    20 by weight of B6 vitramers or their salts and between 80-50% by weight of phytate or its salts. Non-limiting examples of the composition of the invention are the following:


    Composition 1
    Compound Quantity
    Calcium-magnesium phytate 300 mg
    Vitamin B6 50 mg
    Composition 2
    Compound Quantity
    Calcium-magnesium phytate 350 mg
    Vitamin B6 150 mg
    Composition 3
    Compound Quantity
    Calcium-magnesium phytate 400 mg
    Vitamin B6 200 mg
    In another preferred embodiment, the composition is a pharmaceutical composition or a nutraceutical or functional food.
    In the present invention it is understood as "nutraceutical" or "functional food", a food that has a beneficial effect on health. Similarly, the nutraceutical term can be applied to extracts or chemical compounds obtained from common foods. Examples of foods to which properties are attributed
    15 nutraceuticals are olive oil, red wine, broccoli, soybeans etc. Nutraceuticals are normally used in nutritional mixtures and in the pharmaceutical industry. Just as some foods can be classified as nutraceuticals, some nutritional supplements are also classified, such as fatty acids such as omega-3 derived from fish oil and
    20 some vegetables or antioxidants and vitamins.
    The combination of phytate or its salts and B6 vitamins or its salts, can be administered in solid form (including granules, powder or suppositories) or in liquid form (such as solutions, suspensions or emulsions). In turn, they can be administered


    as such or, after being subjected to operations such as sterilization, preservative addition, stabilizer addition or emulsifier addition.
    Vitamins B6 or their pharmaceutically acceptable forms can be used in their pure form or as part of extracts of plant origin that contain them. As an example, there is rice bran (4mg / 100g), pistachio powder (1.7mg / 100g), garlic powder (1.2mg / 100g), liver extract (1mg / 100g), blue fish (1mg / 100g), pipes (0.8mg / 100g) or hazelnuts (0.65mg / 100g).
    The combination of phytate and vitamin B6 can be administered in solid form (including granules, powder or suppositories) or in liquid form (such as solutions, suspensions or emulsions). In turn, they can be administered as such or, after being subjected to operations such as sterilization, preservative addition, stabilizer addition or emulsifier addition.
    Pharmaceutical compositions containing phytate and vitamin B6 will include an amount of each active ingredient that effectively reduces plasma levels of AGEs. In a preferred embodiment of the present invention, said reduction will also be synergistic. The effective amounts for this purpose depend on factors such as the route of administration, the health of the individual or urinary levels of oxalate, although these factors do not limit the inclusion of others that help define the recommended amounts. In any case, it is understood that the amounts of each active ingredient that each individual will take will be determined by a specialist based on each individual circumstance.
    Both phytate and vitamin B6, as well as their combinations can be administered orally, rectally, subcutaneously, intraarterially, intramuscularly, intraspinally, intracranially, intravenously or inhalatively.
    The co-administration of phytate or its salts and B6 vitramers or its salts may be combined with one or more compounds that facilitate its absorption through the selected route of administration. Thus, they can be administered with lactose, sucrose, talc, magnesium stearate, cellulose, calcium salts, gelatin, fatty acids, as well as other similar substances.


    The pharmaceutically acceptable adjuvants and vehicles that can be used in said compositions are the adjuvants and vehicles known to those skilled in the art and commonly used in the elaboration of therapeutic compositions.
    For use in therapy, phytate or its salts and B6 vitramics or their salts will preferably be in a pharmaceutically acceptable or substantially pure form, that is to say that it has a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and not including material considered toxic at normal dosage levels. The purity levels for the active ingredient are preferably greater than 50%, more preferably greater than 70%, and still more preferably greater than 90%. In a preferred embodiment, they are greater than 95% of the compound of formula (I), or of its salts or solvates.
    Although the therapeutic application of the present invention is directed primarily to diabetic patients, phytate or its combination with B6 vitramers may be applicable to any pathological condition in which AGEs occur. The presence of AGEs is associated with irreversible micro and macrovascular complications that include neuropathy, nephropathy, atherosclerosis, vascular calcification and neurodegenerative diseases (Alzheimer's and Parkinson's).
    Throughout the description and the claims the word quot; comprehequot; and its variants are not intended to exclude other technical characteristics, additives, components or steps. For those skilled in the art, other objects, advantages and features of the invention will be derived partly from the description and partly from the practice of the invention. The following examples and figure are provided by way of illustration, and are not intended to be limiting of the present invention. BRIEF DESCRIPTION OF THE FIGURES
    FIG. 1. Levels (mean +/- SD) of glycated hemoglobin (A) and advanced glycation end products (B) before and after phytate treatment and at the visit of


    tracing. The differences between 0 and 3 months; and 3 and 6 months were statistically significant (plt; 0.05).
    FIG. 2. Percentage of inhibition on the AGE formation of phytate (A), pyridoxamine (B) and phytate + pyridoxamine (C) with respect to the control experiment (without inhibitor). The percentage of phytate and pyridoxamine inhibition in combination was significantly higher (plt; 0.05) than these inhibitors separately with the same concentrations. EXAMPLES
    The invention will now be illustrated by tests carried out by the inventors, which demonstrates the effectiveness of the product of the invention.
    Example 1: Effect of the composition of the invention on diabetic patients.
    A clinical trial was conducted in which 1,140 mg of phytate (in the form of phytin: magnesium calcium salt) is administered daily to 33 diabetic patients for 3 months. After this period, the plasma levels of glycated hemoglobin (HbA1c) and AGEs are determined. A statistically significant decrease in both glycated hemoglobin (of the order of 3.9%, p = 0.017) and AGEs (of the order of 25.1%, p <0.001) is observed (see Figure 1). Three months after consuming phytate, its consumption is withdrawn and after three months of bleaching, the plasma levels of HbA1c and AGEs are determined again, observing that their values are increased again until reaching levels similar to the baseline observed before starting the study ( see Figure 1). In turn, an increase in the urinary excretion of phytate of 33.6% (p = 0.026) was observed. These results demonstrate that phytate acts as an inhibitor of the formation of AGEs and GP.
    Example 2: In vitro tests on the effect of phytate in the formation of AGEs
    In an in vitro assay, the inhibitory effect of phytate alone or in combination with pyridoxamine on the formation of AGEs was compared (see Figure 2). It was observed that the effect of the combined use of phytate with pyridoxamine is greater than the effect of these


    two inhibitors separately under their physiological concentrations (phytate: 1 and 2 PM; pyridoxamine: 1 and 2.5 PM). In these studies, the formation of AGEs was induced by incubating at 37 ° C for 7 days (in 0.2M phosphate buffer) a reaction mixture containing ribose (200mM) (taken as model reducing sugar), 1mM of 5 arginine, 2mM of lysine (as glycation targets) and 2ȝM Fe3 + (as glycation catalyst) with different concentrations of phytate and pyridoxamine alone
    or in combination. The amount of AGEs present at 7 days was determined by fluorescence. As can be seen in Figure 2, 1ȝM and 2ȝM of phytate inhibited the formation of AGEs by 12.7% and 19.9% respectively. On the other hand 1ȝM and 10 2.5ȝM of pyridoxamine inhibited the formation of AGEs by 17.5% and 28.2% respectively, compared to the control experience (without inhibitors). However, the combined use of 1ȝM of phytate with 1ȝM or 2.5ȝM of pyridoxamine showed a greater inhibitory effect, of 29.0 and 36.3% respectively. In turn, the combined use of 2ȝM of phytate with 1ȝM or 2.5ȝM of pyridoxamine resulted in
    15 inhibition in the formation of AGEs of 31.6% and 41.9% respectively. These results demonstrate that the inhibitory effect of both pyridoxamine and phytate is superior in its combination than in its use separately, which demonstrates a clear complementary effect between the two.
    20 These models demonstrate that a composition comprising phytate in a form that also contains vitamin B6, can be used for the manufacture of medicines or dietary supplements intended for the treatment of those pathologies caused by an accumulation of AGEs in the body.

    权利要求:
    Claims (14)
    [1]
    one. Use of a composition comprising phytic acid or any of its pharmaceutically acceptable salts for the manufacture of a medicament for the prevention of the formation of glycation end products in diabetic patients, wherein said medicament is prepared for oral, rectal administration, subcutaneous, intraarterial, intramuscular, intraspinal, intracranial, intravenous or inhalation.
    [2]
    2. Use according to claim 1 wherein the composition further comprises a B6 glass or any of its salts.
    [3]
    3. Use according to claim 2 wherein the vitreous B6 is selected from pyridoxine, pyridoxal or pyridoxamine.
    [4]
    Four. Use according to the preceding claim wherein the derivative of vitamin B6 is pyridoxamine.
    [5]
    5. Use according to any of the preceding claims wherein the pharmaceutically acceptable salts of phytic acid are selected from sodium phytate, potassium phytate, calcium phytate, magnesium phytate, zinc phytate, calcicomagnesic phytate or combinations thereof.
    [6]
    6. Use according to the preceding claim wherein the salt of the phytic acid is calcium-magnesium phytate.
    [7]
    7. Use according to any of the preceding claims wherein the phytic acid or its salts come from a part of a plant species rich in phytic acid or its salts, or from a plant extract of said species.
    [8]
    8. Use of a composition comprising phytic acid or any of its pharmaceutically acceptable salts combined sequentially, simultaneously or separately with a B6 glass, for the manufacture of a prepared medicament

    to be administered orally, rectally, subcutaneously, intraarterially, intramuscularly, intraspinally, intracranially, intravenously or inhalatoryly.
    [9]
    9. Composition comprising phytic acid or any of its salts and at least
    5 a derivative of vitamin B6 or any of its salts, wherein said composition is prepared to be administered orally, rectally, subcutaneously, intraarterially, intramuscularly, intraspinally, intracranially, intravenously or inhalatoryly.
    [10]
    10. Composition according to claim 9 wherein the B6 vitramer is selected from 10 among pyridoxine, pyridoxal or pyridoxamine.
    [11]
    11. Composition according to the preceding claim wherein the vitromer B6 is pyridoxamine.
    Composition according to any one of claims 9 to 11 wherein the salt of the phytic acid is selected from sodium phytate, potassium phytate, calcium phytate, magnesium phytate, zinc phytate, calcium-magnesium phytate or combinations thereof.
    [13]
    13. Composition according to the preceding claim wherein the salt of the phytic acid is calcium-magnesium phytate.
    [14]
    14. Composition according to any of claims 9 to 13 wherein the phytic acid or its salts are derived from a part of a plant species rich in phytic acid
    or its salts, or a plant extract of said species. 25
    [15]
    15. Composition according to any of claims 9 to 14 wherein the composition is a pharmaceutical composition or a nutraceutical or functional food.
    16. Use of the composition according to any of claims 9 to 15 for the manufacture of a medicament.
    TO
     8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2
    HbA1c (%)

     DRAWINGS 
     Glycated hemoglobin(HbA1c) 
    0 months 3 months6 months
        (start tto. IP6)             (end tto. IP6)               (tracing)
    FIG. 1A

    B
     Advanced glycation end products (AGEs)
    0 months 3 months6 months
    (start tto. IP6)  (end tto. IP6)(tracing)
    FIG. 1 B

     0.25uMIP6 0.5uMIP6 1uMIP6 2uMIP6
     0.5uMPM 1uMPM 2.5uMPM 5uMPM
    FIG. 2

    1.0uMIP6 + 1.0 1.0uMIP6 + 2.5 2.0uMIP6 + 1.0 2.0uMIP6 + 2.5 uMPM uMPM uMPM uMPM
    FIG. 2 cont.
    类似技术:
    公开号 | 公开日 | 专利标题
    Gröber et al.2016|Micronutrients in oncological intervention
    Andrea Moura et al.2015|Lipoic acid: its antioxidant and anti-inflammatory role and clinical applications
    Šalamon et al.2019|Medical and dietary uses of N-acetylcysteine
    Gould et al.2019|Impact of supplementary amino acids, micronutrients, and overall diet on glutathione homeostasis
    Fassett et al.2011|Astaxanthin: a potential therapeutic agent in cardiovascular disease
    US9180111B2|2015-11-10|Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
    Soda et al.2009|Polyamine-rich food decreases age-associated pathology and mortality in aged mice
    US20050070607A1|2005-03-31|N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
    Fujimoto et al.2019|Mitochondria-targeted antioxidants for treatment of hearing loss: a systematic review
    JP4589999B2|2010-12-01|Methyl donor salt or complex salt with phytic acid or derivatives thereof, and synthesis method thereof
    Principe et al.2011|Trans-plasma membrane electron transport in mammals: functional significance in health and disease
    EP3087064B1|2021-09-15|Prodrugs of urolitihns and uses thereof
    Bulboacă et al.2019|Liposomal curcumin is better than curcumin to alleviate complications in experimental diabetic mellitus
    BR112020012705A2|2020-11-24|lysophosphatidylcholine compositions
    IES20110260A2|2012-02-29|Dietary formulations
    JP5882889B2|2016-03-09|Antitumor agent
    ES2596752B1|2018-03-07|Use of phytic acid or its salts alone or in combination with Vitamin B6 for the prevention of the formation of advanced glycation products
    Wang et al.2020|Docosahexaenoic acid-acylated astaxanthin ester exhibits superior performance over non-esterified astaxanthin in preventing behavioral deficits coupled with apoptosis in MPTP-induced mice with Parkinson's disease
    US20160067295A1|2016-03-10|Walnut extracts for nutraceutical applications
    Bargagli et al.2020|Dietary oxalate intake and kidney outcomes
    McCarty et al.2021|A Fundamental Role for Oxidants and Intracellular Calcium Signals in Alzheimer’s Pathogenesis—And How a Comprehensive Antioxidant Strategy May Aid Prevention of This Disorder
    ES2650918T3|2018-01-23|Ferritin isolation, use and analysis procedures
    Mirskova et al.2011|2-Hydroxyethylammonium Salts of Organylsulphanyl | acetic Acids as Novel Pharmacologically Active Compounds
    EP1278836B1|2010-04-21|Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders
    Jukić et al.2021|Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation
    同族专利:
    公开号 | 公开日
    EP3320905A4|2019-02-27|
    WO2017009506A1|2017-01-19|
    EP3320905A1|2018-05-16|
    US20180214463A1|2018-08-02|
    ES2596752B1|2018-03-07|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CN112002946A|2020-08-06|2020-11-27|山东科技大学|Preparation method and application of polyaniline zinc ion battery of high-voltage platform|US5211956A|1988-05-19|1993-05-18|Sanwa Kagaku Kenkyusho Co., Ltd.|Pharmaceutical compositions containing phytic acid or its salts|
    JP2010195734A|2009-02-26|2010-09-09|Nisshin Pharma Inc|Phytic acid, carboxylic acid, and composition having fat absorption inhibitory action by synergistic effect of saccharides|
    法律状态:
    2018-03-07| FG2A| Definitive protection|Ref document number: 2596752 Country of ref document: ES Kind code of ref document: B1 Effective date: 20180307 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201531010A|ES2596752B1|2015-07-10|2015-07-10|Use of phytic acid or its salts alone or in combination with Vitamin B6 for the prevention of the formation of advanced glycation products|ES201531010A| ES2596752B1|2015-07-10|2015-07-10|Use of phytic acid or its salts alone or in combination with Vitamin B6 for the prevention of the formation of advanced glycation products|
    EP16823926.7A| EP3320905A4|2015-07-10|2016-07-08|Use of phytic acid or the salts thereof, alone or combined with b6 vitamers, for preventing the formation of advanced glycation end-products|
    US15/742,996| US20180214463A1|2015-07-10|2016-07-08|Use of phytic acid or the salts thereof, alone or combined with b6 vitamers, for preventing the formation of advanced glycation end-product|
    PCT/ES2016/070515| WO2017009506A1|2015-07-10|2016-07-08|Use of phytic acid or the salts thereof, alone or combined with b6 vitamers, for preventing the formation of advanced glycation end-products|
    [返回顶部]